Managing Early Toxicity and Preserving Adherence in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

In this segment, the discussion shifts to a 70 year old patient with EGFR mutated metastatic non-small cell lung cancer who is experiencing dermatologic toxicity several months into first line EGFR targeted therapy. With an ECOG performance status of 2 and concerns about quality of life, the case highlights the real world challenges of sustaining long term treatment.

Dr. Singhi emphasizes that early recognition and proactive management of adverse events are essential to maintaining adherence. He discusses reassessing supportive care measures, reinforcing dermatologic prophylaxis, and intensifying topical or systemic interventions as needed. Close follow up, patient education, and multidisciplinary involvement are described as critical components of care. The conversation underscores that effective toxicity management is not solely about maintaining dose intensity but about preserving functional status and independence. This segment illustrates how individualized supportive strategies can help patients remain on effective therapy in EGFR mutated metastatic non-small cell lung cancer.